These are supportive clinical data but not a near-term catalyst — the Phase 3 pediatric studies are still ongoing, and no regulatory filing was announced. The 42% ≥30% LDL-C reduction in CLEAR Outcomes is an incremental positive for the product's on-label messaging. Expect limited stock reaction unless subsequent regulatory news (FDA sNDA filing for pediatric indication) emerges. If you have a position, wait for concrete regulatory milestones.
Price Chart
Executive Summary
Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid reduced LDL-C in children (range 6-25%) without new safety concerns, and that 42% of statin-intolerant adults achieved ≥30% LDL-C reduction. These data support ongoing Phase 3 pediatric studies and reinforce the product profile, but are interim scientific presentations without a hard regulatory catalyst or financial update.
Key Facts
- Phase 2 study in children aged 6-17 with HeFH showed weight-based bempedoic acid dosing produced adult-equivalent exposure and LDL-C reductions of 6-25% with no new safety signals.
- CLEAR Outcomes post-hoc analysis: 42% of statin-intolerant adults on bempedoic acid achieved ≥30% LDL-C reduction at 3 months, comparable to moderate-intensity statins.
- Factors associated with ≥30% LDL-C reduction included female sex, higher baseline LDL-C, and concurrent ezetimibe use.
- No new regulatory approvals, label expansions, financial results, or guidance were announced in this press release.
Financial Impact
No financial figures disclosed; data support potential label expansion to pediatric population and commercial differentiation.
Risk Factors
- Phase 3 pediatric study results could differ from Phase 2, delaying or preventing label expansion.
- Competition from newer non-statin LDL-C therapies (e.g., PCSK9 inhibitors, oral siRNA) could pressure commercial adoption.
- Esperion remains dependent on single-drug revenue; a pipeline setback would be disproportionately impactful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300994 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access